Venova Medical

Venova Medical, Inc. is a privately held company focused on developing innovative solutions for vascular access in hemodialysis patients. The company's primary product is the Velocity Percutaneous Arterio-Venous Fistula (pAVF) System, which is designed to address the challenges associated with creating optimal vascular access for hemodialysis. The Velocity System aims to streamline the process of creating functional dialysis access without the need for follow-up interventions.

The Velocity pAVF System is positioned as a next-generation vascular access technology that offers several advantages over traditional surgical methods. It is designed to be less invasive, provide faster recovery times, and reduce the risk of complications. Additionally, the system aims to allow for earlier cannulation compared to surgical arteriovenous fistulas (AVFs). A key feature of the Velocity System is its potential to reduce the need for reinterventions during the fistula maturation process, which is a common issue with current pAVF procedures. Studies have shown that reintervention rates for existing pAVF procedures can range from 20% to 50%, often requiring one or more additional procedures to achieve adequate fistula maturation before use in hemodialysis.

Venova Medical's technology aims to address significant challenges in the hemodialysis field. As of 2022, there were nearly 500,000 individuals on hemodialysis in the US, with 62.6% of patients dialyzing via an arteriovenous fistula, which is considered the preferred vascular access option. By developing a system that potentially reduces complications and improves outcomes, Venova Medical seeks to enhance the quality of care for hemodialysis patients while potentially lowering healthcare costs.